Lunai Bioworks Proposes Second Reverse Stock Split (1-for-3 to 1-for-30) to Avoid Nasdaq Delisting

summarizeSummary

Lunai Bioworks Inc. is seeking shareholder approval for another reverse stock split, ranging from 1-for-3 to 1-for-30, to boost its share price and maintain its Nasdaq listing, following a previous reverse split that failed to prevent a new delisting notice.

check_boxKey Events

• Proposed Second Reverse Stock Split

  Shareholders will vote on a proposal to amend the company's Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-3 and 1-for-30, at the Board's discretion.

• Urgent Nasdaq Listing Compliance

  The primary reason for the proposed reverse split is to increase the per-share trading price to regain compliance with Nasdaq's $1.00 minimum bid price requirement. This follows a delisting notice received on February 6, 2026, and a prior 1-for-10 reverse split in September 2025 that failed to maintain compliance.

• Potential for Future Dilution

  The number of authorized shares will remain unchanged at 350,000,000, which will significantly increase the number of authorized but unissued shares available for future issuance, potentially leading to further dilution.

• Special Meeting Scheduled

  A special meeting of stockholders is scheduled for May 4, 2026, to vote on the reverse stock split proposal and an adjournment proposal.

auto_awesomeAnalysis

This preliminary proxy statement reveals Lunai Bioworks' urgent attempt to address its precarious Nasdaq listing status by proposing a second reverse stock split within seven months. The company previously executed a 1-for-10 split in September 2025, which failed to sustain the stock price above the $1.00 minimum, leading to a new delisting notice and a Nasdaq hearing. While intended to prevent delisting, a reverse split often signals underlying operational or financial challenges and can be viewed negatively by investors. The wide proposed ratio range (1-for-3 to 1-for-30) underscores the uncertainty regarding the necessary price adjustment. Furthermore, keeping authorized shares unchanged significantly increases the potential for future dilutive capital raises, which is a concern for a company already facing a "going concern" warning and material weaknesses in internal controls. Investors should monitor the outcome of the Nasdaq hearing and the shareholder vote, as well as any subsequent capital raising activities.